Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression

Clinical and Experimental Dermatology

Volumn 42, Issue 3, 2017, Pages 309-312

  Rofe, O ^a   Bar Sela, G ^a   Keidar, Z ^a   Sezin, T ^b   Sadik, C D ^b   Bergman, R ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETAMETHASONE; CORTICOSTEROID; FLUORODEOXYGLUCOSE; IMMUNOGLOBULIN G; IPILIMUMAB; LEVOTHYROXINE; METHOTREXATE; METHYLPREDNISOLONE; PEMBROLIZUMAB; PREDNISONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMEN; ADRENAL INSUFFICIENCY; ADULT; ANTIBODY TITER; ARTICLE; BLISTER; BULLOUS PEMPHIGOID; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CONTROLLED STUDY; DERMOEPIDERMAL JUNCTION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; LYMPH NODE METASTASIS; MEDIASTINUM; METASTATIC MELANOMA; MIDDLE AGED; MONONUCLEAR CELL; PAPILLARY DERMIS; PAPULAR RASH; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PUNCH BIOPSY; REMISSION; SERUM; SKIN BIOPSY; SKINFOLD THICKNESS; THYROID DISEASE; TREATMENT RESPONSE; CHEMICALLY INDUCED; IMMUNOLOGY; MELANOMA; PEMPHIGOID, BULLOUS; SECONDARY; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MELANOMA; MIDDLE AGED; PEMPHIGOID, BULLOUS; SKIN NEOPLASMS;

EID: 85013314020     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.13042     Document Type: Article

References (10)

1. Thoma-Uszynski S, Uter W, Schwietzke S et al. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J Immunol 2006; 176: 2015–23.
2. Arakawa M, Dainichi T, Ishii N et al. Lesional Th17 cells and regulatory T cells in bullous pemphigoid. Exp Dermatol 2011; 20: 1022–4.
3. Kong Yi-Chi M, Flynn JC. Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1. Front Immunol 2014; 5: 1–8.
4. Hodl FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23.
5. Kaehler KC, Piel S, Livingstone E, Schilling B et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010; 37: 485–98.
6. Carlos G, Anforth R, Chou S et al. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res 2015; 25: 265–8.
7. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219–42.
8. Echigo T, Hasegawa M, Shimada Y et al. Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases. Arch Dermatol 2006; 298: 38–45.
9. + regulatory T cells in bullous pemphigoid. Dermatol 2007; 16: 13–21.
10. Torchia D, Caproni M, Volpi W, Fabbri P. Naturally occurring regulatory T cells in mucous membrane pemphigoid lesions. Acta Dermatovenereol 2009; 18: 3–6.